The use of cannabinoids in chronic pain.

“We present the case of a 56-year-old man who developed chronic pain following the excision of a facial cancer that was poorly controlled despite multiple analgesic medications. Following the starting of nabilone (a synthetic cannabinoid) his pain control was greatly improved and this had a huge impact on his quality of life.

We also managed to significantly reduce his doses of opioid analgesia and ketamine.

We review the current literature regarding the medicinal use of cannabinoids, with an emphasis on chronic pain, in an attempt to clarify their role and how to select patients who may benefit from this treatment.”

http://www.ncbi.nlm.nih.gov/pubmed/23893276

Cannabidiol Normalizes Caspase 3, Synaptophysin, and Mitochondrial Fission Protein DNM1L Expression Levels in Rats with Brain Iron Overload: Implications for Neuroprotection.

“We have recently shown that chronic treatment with cannabidiol (CBD) was able to recover memory deficits induced by brain iron loading in a dose-dependent manner in rats.

 Brain iron accumulation is implicated in the pathogenesis of neurodegenerative diseases, including Parkinson’s and Alzheimer’s, and has been related to cognitive deficits in animals and human subjects.

…we have analyzed the expression level of brain proteins involved with mitochondrial fusion and fission mechanisms (DNM1L and OPA1), the main integral transmembrane protein of synaptic vesicles (synaptophysin), and caspase 3, an apoptosis-related protein, to gain a better understanding of the potential of CBD in restoring the damage caused by iron loading in rats.

We found that CBD rescued iron-induced effects…

Our results suggest that iron affects mitochondrial dynamics, possibly trigging synaptic loss and apoptotic cell death and indicate that CBD should be considered as a potential molecule with memory-rescuing and neuroprotective properties to be used in the treatment of cognitive deficits observed in neurodegenerative disorders.”

http://www.ncbi.nlm.nih.gov/pubmed/23893294

Activation of spinal cannabinoid cb2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice.

“The role of spinal cannabinoid systems in neuropathic pain of streptozotocin-induced diabetic mice was studied…

 … A low dose of WIN-55,212-2  significantly recovered the tail-flick latency in streptozotocin-induced diabetic mice… The selective cannabinoid CB2 receptor agonist L-759,656 also dose-dependently recovered the tail-flick latency in streptozotocin-induced diabetic mice…

 These results indicate that spinal cannabinoid systems are changed in diabetic mice and suggest that cannabinoid CB2 receptor agonists might have an ability to recover diabetic neuropathic pain.”

http://www.ncbi.nlm.nih.gov/pubmed/23892011

The Hypocretin/Orexin Receptor-1 as a Novel Target to Modulate Cannabinoid Reward.

“Although there is a high prevalence of users who seek treatment for cannabis dependence, no accepted pharmacologic treatment is available to facilitate and maintain abstinence.

 The hypocretin/orexin system plays a critical role in drug addiction, but the potential participation of this system in the addictive properties of cannabinoids is unknown.

 We investigated…  studies were performed to evaluate dopamine extracellular levels in the nucleus accumbens after acute Δ9-tetrahydrocannabinol administration..

… role of Hcrtr-1 in the reinforcing and motivational properties of WIN55,212-2 (THC) was confirmed…

CONCLUSIONS:

These findings demonstrate that Hcrtr-1 modulates the reinforcing properties of cannabinoids, which could have a clear therapeutic interest.”

http://www.ncbi.nlm.nih.gov/pubmed/23896204

The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.

“Endogenous cannabinoids (EC) are ubiquitous lipid signalling molecules providing different central and peripheral effects that are mediated mostly by the specific receptors CB1 and CB2. The EC system is highly upregulated during chronic liver disease and consistent experimental and clinical findings indicate that it plays a role in the pathogenesis of liver fibrosis and fatty liver disease associated with obesity, alcohol abuse and hepatitis C.

Furthermore, a considerable number of studies have shown that EC and their receptors contribute to the pathogenesis of the cardio-circulatory disturbances occurring in advanced cirrhosis, such as portal hypertension, hyperdynamic circulatory syndrome and cirrhotic cardiomyopathy.

More recently, the EC system has been implicated in the development of ascites, hepatic encephalopathy and the inflammatory response related to bacterial infection. Rimonabant, a selective CB1 antagonist, was the first drug acting on the EC system approved for the treatment of obesity. Unfortunately, it has been withdrawn from the market because of its neuropsychiatric side effects.

Compounds able to target selectively the peripheral CB1 receptors are under evaluation.

In addition, molecules stimulating CB2 receptor or modulating the activity of enzymes implicated in EC metabolism are promising areas of pharmacological research.

Liver cirrhosis and the related complications represent an important target for the clinical application of these compounds.”

http://www.ncbi.nlm.nih.gov/pubmed/23890208

Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors.

“∆9 -Tetrahydrocannabinol (THC), the active constituent of Cannabis sativa, exerts its biological effects in part through the G-protein-coupled CB1 and CB2 receptors, which were initially discovered in brain and spleen tissue, respectively. However, THC also has CB1/2 receptor-independent effects. Because of its immune-inhibitory potential, THC and related cannabinoids are being considered for the treatment of inflammatory skin diseases.

Here we investigated the mechanism of the anti-inflammatory activity of THC and the role of CB1 and CB2 receptors…

CONCLUSIONS:

Topically applied THC can effectively attenuate contact allergic inflammation by decreasing keratinocyte-derived pro-inflammatory mediators that orchestrate myeloid immune cell infiltration independent of CB1/2 receptors.

This has important implications for the future development of strategies to harness cannabinoids for the treatment of inflammatory skin diseases.”

http://www.ncbi.nlm.nih.gov/pubmed/23889474

Marijuana cannabinoids found to help combat autism

cannabinoids

“(NaturalNews) The cannabinoid compounds naturally found in many varieties of cannabis, also known more commonly as marijuana, may help children with autism spectrum disorders experience dramatic behavioral improvements, and potentially even full recovery from their symptoms. These are the findings of a new study published in the journal Nature Communications that help reinforce the growing body of evidence which shows that medicinal cannabinoids hold incredible potential in both treating and potentially curing chronic illness…
 

Can non-psychoactive cannabinoid compounds actually cure chronic illness?

Though the researchers were quick to deny that cannabinoids hold any potential at actually curing autism, which more than likely was a politically-motivated denial rather than a factual admission, other research and actual case studies suggest that cannabinoid compounds are, indeed, powerful enough to mitigate many or all of the symptoms associated with autism, as well as many other diseases.”

 

Stanford University Study Finds That Marijuana Could Help With Autism

“A study conducted by Stanford University has found that there might be compounds in marijuana which have some very specific health benefits. The study’s results reveal that cannabinoids – which are found in cannabis – might help to treat autism.”

article image

“A new study shows that mutations associated with autism block the action of brain molecules that act on the same receptors that marijuana’s active chemical acts on,” according to the Autism Daily Newscast. “Thomas Sudhof, a cellular physiologist at Stanford University, tested mutations associated with autism in mice. Two mutations associated with autism in a synapse-adhesion protein led to deficits in prolonged endocannabinoid signaling in mice. This suggests that autism could caused by a disruption of the brain’s ability to send clear signals.
 
ADN references another study that supports the theory that cannabinoids could be used as a treatment to autism…”
 

More: http://www.opposingviews.com/i/health/stanford-university-study-finds-marijuana-could-help-autism#

Study Finds Cannabis May Provide Treatment For Autism

“A new study out of Standford University has found promising signs to suggest that cannabinoids – compounds found in cannabis, as well as naturally produced in our body – may help to treat autism.

According to Autism Daily Newscast (ADN); ”A new study shows that mutations associated with autism block the action of brain molecules that act on the same receptors that marijuana’s active chemical acts on”.

They continue: “Thomas Sudhof, a cellular physiologist at Stanford University, tested mutations associated with autism in mice. Two mutations associated with autism in a synapse-adhesion protein led to deficits in prolonged endocannabinoid signaling in mice. This suggests that autism could caused by a disruption of the brain’s ability to send clear signals”.

These findings suggest that cannabinoids could be used as a treatment to autism as they can unblock a disruption in the body’s cannabinoid receptors…”

More: http://www.theweedblog.com/study-finds-cannabis-may-provide-treatment-for-autism/

Hope for autistic children might lie in medical marijuana, study says – msn

Marijuana in a prescription bottle (© Gary Morrison/Getty Images)

“Stanford University released a study that will most likely add more fuel to the already contentious debate over medical marijuana, especially regarding its possible use by kids. The study, released in April, shows that cannabinoids, which are found in cannabis, might help treat autism. In the human brain, endocannabinoid signaling affects memory formation, learning, and other processes, but forms of autism can block these signals. When cannabinoids were present in the brains of mice being studied, these signals were able to get through. While more research is needed, autism groups are hopefull about the possibilties of medical marijuana. As the Autism Daily Newscast put it, “Many children with autism are already given cocktails of drugs that may be even stronger than marijuana, with serious side effects and limited results.”

http://now.msn.com/marijuana-affects-autism-by-helping-brain-signals-get-through-says-stanford-study